Table 4.

ORs of low-grade and high-grade prostate cancer by serum protein carbonyl levels

GradeProtein carbonyl (nmol/mL)*
Q1 (<17.35)Q2 (17.5-19.5)Q3 (19.6-22.1)Q4 (>22.1)P-trend
nnOR (95% CI)nOR (95% CI)nOR (95% CI)
Combined armLow-grade (n = 1,229)3282840.89 (0.72-1.09)3181.04 (0.85-1.28)2991.00 (0.82-1.24)0.6
High-grade (n = 495)1271140.96 (0.72-1.28)1341.12 (0.85-1.48)1201.02 (0.77-1.36)0.61
Finasteride armLow-grade (n = 449)1141101.14 (0.81-1.60)1121.12 (0.8-1.57)1131.28 (0.91-1.79)0.19
High-grade (n = 278)67601.11 (0.74-1.68)841.39 (0.95-2.05)671.25 (0.83-1.87)0.16
Placebo armLow-grade (n = 780)2141740.75 (0.58-0.98)2060.99 (0.76-1.29)1860.86 (0.66-1.12)0.66
High-grade (n = 217)60540.82 (0.55-1.24)500.85 (0.56-1.30)530.84 (0.56-1.27)0.47

NOTE: Low-grade, Gleason <7; high-grade, Gleason ≥7. All ORs were adjusted for age, race (white vs nonwhite), education (<HS, HS, ≥HS), smoking status (current, past, never), and physical activity (moderate or active vs sedentary or light). P-trend values were calculated by assigning values of 1/2/3/4 to OP quartiles and then treating as continuous.

  • *Quartile values were calculated based on controls only.

  • OR for low-grade and high-grade cancers were modeled by polychotomous logistic regression; both cancers are contrasted with controls in the same model.